US targets Chinese biotech investment, but licensing deals remain exempt
The US government is seeking to curb American investment in Chinese firms involved in advanced drug development after adding the…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Roche’s pharma sales grow 7% but pipeline trimmed down
Roche posted a healthy 7% growth for its pharmaceutical division in the first nine months of 2026, though the drugmaker…
-
FDA approves GSK’s Hibsago as first functional cure for hepatitis B
The US Food and Drug Administration (FDA) has approved GSK’s Hibsago (bepirovirsen), marking the first functional cure available to hepatitis…
-
AbbVie races into F1 as pharma companies continue push into sport
AbbVie has continued its recent foray into sport by striking a partnership with Formula 1 (F1) team McLaren, reflecting a…
-
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revoked approval for Valneva’s chikungunya vaccine after deciding that the…
-
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics
Merck KGaA has agreed to buy short interfering RNA (siRNA) drug developer Silence Therapeutics for $1.3bn, giving the German pharma…
-
MHRA could allow schools to hold reserves of nasal adrenaline spray
UK children at risk of anaphylaxis could soon have another treatment option available at school, after the Medicines and Healthcare…
-
Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes
A European Medicines Agency (EMA) panel has backed Eli Lilly’s Foundayo (orforglipron) for approval, helping the drugmaker close the gap…
-
RevMed’s pancreatic cancer drug inches closer to EU approval after panel’s backing
A European Medicines Agency (EMA) panel has recommended approval of Revolution Medicines’ Rasonque (daraxonrasib) for certain pancreatic cancer patients, marking…
-
Rare disease regulation reaches “inflection point” with new FDA framework
The US Food and Drug Administration (FDA) has rolled out a new framework to spur development of new therapies for…